Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM
MNPR Stock Price Increases Over 30% Pre-Market: Why It Happened
08:20am, Thursday, 11'th Feb 2021
The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) is trading at over 30% pre-market today. This is why it happened.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics desi
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
07:00am, Tuesday, 09'th Feb 2021
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designe
Why Monopar Therapeutics And EyePoint Pharma Are Trading Higher Today
12:37pm, Thursday, 28'th Jan 2021
Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of $49 per share. Monopar Therapeutics is
MNPR Stock Price Increases Over 100% Pre-Market: Why It Happened
08:47am, Thursday, 28'th Jan 2021
The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) has increased over 100% pre-market today. This is why it happened.
Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%
09:47am, Monday, 28'th Dec 2020
Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
08:30am, Tuesday, 22'nd Dec 2020
-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
08:30am, Thursday, 10'th Dec 2020
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminog
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
12:30pm, Wednesday, 19'th Aug 2020
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI)
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
12:30pm, Wednesday, 12'th Aug 2020
Potential Companion Diagnostic to Monopar’s uPRIT ProgramWILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to pote
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
12:30pm, Monday, 10'th Aug 2020
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), wh
JonesTrading Thinks Monopar Therapeutics Inc's Stock is Going to Recover - Markets
02:05pm, Friday, 07'th Aug 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPR – Research
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
08:05pm, Thursday, 06'th Aug 2020
Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 TechnologyCHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasd
